Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients

Table 1 Characteristics of 41 patients in II and III line and tumours

	Number of patients	Rates	Median age (range) yr
Gender
Male (M)	23	56%	67.5 (51-84)
Female (F)	18	44%	64.6 (49-83)
Primary tumour
Right colon	7	17%
Left colon	21	51%
Rectal	13	32%
Grade
G1/G2	27	65.8%
G3	13	31.7%
NA	1	2.5%
Metastasis
Liver only	12	29.3%
Liver plus other sites	14	34.1%
Extra-hepatic sites	15	36.6%
Response
Responders
CR	4	9.8%
PR	12	29.3%
SD	8	19.5%
Non-responders
PD	17	41.4%
Line of treatment
II	33	8%
III	8	2%

NA: Not available; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.